GERARDO MAZZELLA

 GERARDO MAZZELLA

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.

ClinicalTrials.gov

Find StudiesFind Studies Menu

About StudiesAbout Studies Menu

Submit StudiesSubmit Studies Menu

ResourcesResources Menu

About SiteAbout Site Menu

HomeSearch ResultsStudy Record Detail Save this study

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Gerardo Mazzella

 

ClinicalTrials.gov Identifier: NCT03230318

Recruitment Status  : Recruiting

First Posted  : July 26, 2017

Last Update Posted  : July 10, 2020

See Contacts and Locations

Sponsor:

Basilea Pharmaceutica

Information provided by (Responsible Party):

Basilea Pharmaceutica

Study DetailsTabular ViewNo Results PostedDisclaimerHow to Read a Study Record

Study Description

Go to  sections

Brief Summary:

This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1 in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors harbor FGFR2 gene fusions (by FISH performed by the central laboratory) or FGFR2 gene mutations or amplifications (based on NGS testing performed or commissioned by the respective study center) and who received at least one prior regimen of systemic therapy. Subjects will be dosed orally once per day at 300 mg of derazantinib capsules.

Condition or disease Intervention/treatment Phase 

Intrahepatic Cholangiocarcinoma

Combined Hepatocellular and Cholangiocarcinoma

Drug: derazantinib

Phase 2

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Study Design

Go to  sections

Study Type  : Interventional  (Clinical Trial)

Estimated Enrollment  : 143 participants

Allocation: N/A

Intervention Model: Single Group Assignment

Masking: None (Open Label)

Primary Purpose: Treatment

Official Title: A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications

Actual Study Start Date  : November 10, 2017

Estimated Primary Completion Date  : July 2020

Estimated Study Completion Date  : March 2021

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Crouzon syndrome Pfeiffer syndrome Cholangiocarcinoma

MedlinePlus related topics: Genes and Gene Therapy

Genetic and Rare Diseases Information Center resources: Bile Duct Cancer Crouzon Syndrome Pfeiffer Syndrome Intrahepatic Cholangiocarcinoma Biliary Tract Cancer

U.S. FDA Resources

Arms and Interventions

Go to  sections

Arm Intervention/treatment 

Experimental: derazantinib

Oral administration

Drug: derazantinib

derazantinib will be orally administered at 300 mg once per day one hour prior to or two hours after a meal and is supplied as 100 mg capsules.

Outcome Measures

Go to  sections

Primary Outcome Measures  :

Substudy 1: Anti-cancer activity of derazantinib by Objective Response Rate (ORR) [ Time Frame: Up to approximately 32 weeks ]

ORR will be assessed by central radiology review as per RECIST version 1.1

Substudy 2: Anti-tumor activity of derazantinib by Progression Fress Survival at 3 months (PFS 3) [ Time Frame: 3 months ]

PFS 3 will be assessed based on survival status or central radiology review (Response Evaluation Criteria in Solid Tumors, RECIST 1.1)

Secondary Outcome Measures  :

Safety of derazantinib as assessed by adverse events [ Time Frame: Up to approximately 36 weeks ]

Adverse events will be graded using NCI CTCAE guidelines, version 4.03

Anti-cancer activity of derazantinib by duration of response (DoR) [ Time Frame: Up to approximately 32 weeks ]

DoR will be assessed by central radiology review per RECIST version 1.1

Anti-cancer activity of derazantinib by progression free survival (PFS) [ Time Frame: Up to approximately 32 weeks ]

PFS will be assessed by central radiology review per RECIST version 1.1

Anti-cancer activity of derazantinib by overall survival (OS) [ Time Frame: Up to approximately 36 weeks ]

OS will be calculated from the first date of receiving study drug until death

Health-related quality of life as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire [ Time Frame: Up to approximately 36 weeks ]

Health-related quality of life as assessed by the EORTC QLQ-BIL21 questionnaire [ Time Frame: Up to approximately 36 weeks ]

Health-related quality of life as assessed by the EuroQol EQ-5D questionnaire [ Time Frame: Up to approximately 36 weeks ]

Substudy 2: Anti-cancer activity of derazantinib by Objective Response Rate [ Time Frame: Up to approximately 32 weeks ]

ORR will be assessed by central radiology review as per RECIST version 1.1

Eligibility Criteria

Go to  sections

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:  18 Years and older   (Adult, Older Adult)

Sexes Eligible for Study:  All

Accepts Healthy Volunteers:  No

Criteria

Inclusion Criteria:

Signed written informed consent granted prior to initiation of any study-specific procedures

18 years of age or older

Histologically or cytologically confirmed locally advanced, inoperable (where surgery is not indicated due to disease extension, co-morbidities, or other technical reasons), or metastatic iCCA or mixed histology tumors (combined hepatocellular-cholangiocarcinoma [cHCC-CCA])

Substudy 1: FGFR2 gene fusion status based on the following assessments:

If central laboratory designated by Sponsor:

Positive FISH test; and/or

If non-central laboratory:

i) Positive FISH or NGS test: patients may be enrolled and may start dosing, but central confirmation is required* ii) Negative FISH or NGS test: tissue may be submitted to the central laboratory designated by the Sponsor, and patients may only be enrolled if the central test is positive

*Using standard protocols and approved by local IRB/EC, by CLIA or other similar agency.

Substudy 2: FGFR2 mutation status based on local NGS testing performed or commissioned by the respective study site using a validated test. For NGS testing, no central laboratory will be established for the purpose of Substudy 2.

Received at least one regimen of prior systemic therapy and then experienced documented radiographic progression

Measurable disease by RECIST version 1.1 criteria

ECOG performance status ≤ 1

Adequate organ functions as indicated by the following laboratory values (based on screening visit values from the central laboratory).

Hematological

Hemoglobin (Hgb) ≥ 9.0 g/dL

Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

Platelet count ≥ 75 x 109/L

International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ≤ 3 for subjects receiving anticoagulant therapy such as Coumadin or heparin

Hepatic

Total bilirubin ≤ 2 x ULN

AST and ALT ≤ 3 ULN (≤ 5 x ULN for subjects with liver metastases)

Albumin ≥ 2.8 g/dL

Renal

Serum creatinine ≤ 1.5 x ULN

Creatinine clearance of ≥ 60 mL/min as estimated by the Cockcroft-Gault equation

Female and male patients of child-producing potential must agree to avoid becoming pregnant or impregnating a partner, respectively, use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse, during the study*, and until at least 120 for 90 days after the last dose of derazantinib.

*From the day of first study medication, or for oral contraception from 14 days before first study medication.

Male patients are considered not to be of child-producing potential if they have azoospermia (whether due to vasectomy or an underlying medical condition). Female patients are considered not to be of child-producing potential if they are:

postmenopausal* , or

have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening, or

have a congenital or acquired condition that prevents childbearing.

Male or female patients of child-producing potential must agree to comply with one of the following until at least 120 days after the last dose of derazantinib:

Abstinence from heterosexual activity**

Using (or having their partner use) an acceptable method of contraception during heterosexual activity. Acceptable methods of contraception are***:

any ONE of:

- an intrauterine device (IUD)

- vasectomy of a female patient's male partner

- a contraceptive rod implanted into the skin.

any TWO in combination of:

- diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide)

- cervical cap with spermicide (nulliparous women only)

- contraceptive sponge (nulliparous women only)

- male condom or female condom (cannot be used together)

hormonal contraceptive (oral contraceptive pill [estrogen/progestin pill or progestin-only pill], contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection)

*Postmenopausal is defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post -menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is not sufficient.

**Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if it is consistently employed as the subject's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ERCs/IRBs. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

If a contraceptive method listed above is restricted by local regulations/guidelines, then it does not qualify as an acceptable method of contraception for subjects participating at sites in this country/region.

Exclusion Criteria:

Systemic anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of derazantinib, or within five half-lives of any investigational or licensed medicinal product, whichever is the longer period.

Major surgery, locoregional therapy, or radiation therapy within four weeks of the first dose of derazantinib

Previous treatment with any FGFR inhibitor (e.g., ponatinib, dovitinib, nintedanib, AZD4547, NVP-BGJ398, LY2784455, BAY1163877)

- Subjects who received less than four weeks of therapy and were unable to continue therapy due to toxicity will be allowed to participate

Unable or unwilling to swallow the complete daily dose of derazantinib capsules

Clinically unstable central nervous system (CNS) metastases (to be eligible, subjects must have stable disease ≥ 3 months, confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and/or have CNS metastases well controlled by low-dose steroids, anti-epileptics, or other symptom-relieving medications)

Current evidence of corneal or retinal disorder, including but not limited to bullous/band keratopathy, keratoconjunctivitis, corneal abrasion, inflammation/ulceration, confirmed by ophthalmologic examination

Concurrent uncontrolled or active hepatobiliary disorders, untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, biloma or abscess (to be eligible, the subjects have to be treated and disorders/complications should be resolved within 2 weeks prior to the first dose of derazantinib)

History of significant cardiac disorders:

- Myocardial infarction (MI) or congestive heart failure defined as Class II to IV per the New York Heart Association (NYHA) classification within 6 months of the first dose of derazantinib (MI that occurred > 6 months prior to the first dose of derazantinib will be permitted)

- QTcF >450 msec (males or females)

Serum electrolyte abnormalities defined as follows:

- Hyperphosphataemia: Serum phosphate > institutional ULN

- Hyperkalemia: > 6.0 mmol/L

- Hypokalemia: < 3.0 mmol/L

- Hypercalcemia: corrected serum calcium < 1.75 mmol/L (< 7.0 mg/dL)

Hypocalcemia: corrected serum calcium > 3.1 mmol/L (> 12.5 mg/dL)

Hypomagnesemia: < 0.4 mmol/L (< 0.9 mg/dL)

Significant gastrointestinal disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of derazantinib (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)

Previous malignancy within 2 years of the first dose of derazantinib, except curatively treated or low grade malignancies such as non-melanoma skin cancer, carcinoma in-situ of the breast, cervix, and superficial bladder tumors

Concurrent uncontrolled illness not related to cancer, including but not limited to:

Psychiatric illness/substance abuse/social situation that would limit compliance with study requirements

Known uncontrolled human immunodeficiency virus (HIV) infection

Blood or albumin transfusion within 5 days of the blood draw being used to confirm eligibility

Pregnant or breast feeding

Known hypsersensitivity to derazantinib, or to any of the study drug excipients (starch, lactose, crospovidone, magnesium stearate)

Contacts and Locations

Go to  sections

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03230318

Contacts

Contact: Stephan Braun, MD +41 61 606 12 25 stephan.braun@basilea.com

Contact: Frédérique Cantero, MD +41 61 606 1329 frederique.cantero@basilea.com

Locations

Show Show 39 study locations

Sponsors and Collaborators

Basilea Pharmaceutica

Investigators

Study Director: Stephan Braun, MD Basilea Pharmaceutica

More Information

Go to  sections

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019 Jan;120(2):165-171. doi: 10.1038/s41416-018-0334-0. Epub 2018 Nov 13.

Responsible Party: Basilea Pharmaceutica

ClinicalTrials.gov Identifier: NCT03230318     History of Changes

Other Study ID Numbers: DZB-CS-301

ARQ 087-301 ( Other Identifier: ArQule, Inc )

First Posted: July 26, 2017    Key Record Dates

Last Update Posted: July 10, 2020

Last Verified: July 2020

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes

Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Basilea Pharmaceutica:

iCCA

intrahepatic cholangiocarcinoma

FGFR2 gene fusion or FGFR2 gene mutation or amplification

biliary cancer

bile duct cancer

FGFR2 gene rearrangement

liver cancer

targeted therapy

combined hepatocellular and cholangiocarcinoma

cHCC-CCA

derazantinib

Additional relevant MeSH terms:

Cholangiocarcinoma

Carcinoma, Hepatocellular

Adenocarcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms

Liver Neoplasms

Digestive System Neoplasms

Neoplasms by Site

Digestive System Diseases

Liver Diseases

TO TOP

For Patients and Families For Researchers For Study Record Managers

HOME RSS FEEDS SITE MAP TERMS AND CONDITIONS DISCLAIMER CUSTOMER SUPPORT

Copyright Privacy Accessibility Viewers and Players Freedom of Information Act USA.gov

U.S. National Library of Medicine U.S. National Institutes of Health U.S. Department of Health and Human Services